505 related articles for article (PubMed ID: 31980166)
1. The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Chowdhury B; Luu AZ; Luu VZ; Kabir MG; Pan Y; Teoh H; Quan A; Sabongui S; Al-Omran M; Bhatt DL; Mazer CD; Connelly KA; Verma S; Hess DA
Biochem Biophys Res Commun; 2020 Mar; 524(1):50-56. PubMed ID: 31980166
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
[TBL] [Abstract][Full Text] [Related]
4. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
[No Abstract] [Full Text] [Related]
5. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats.
Lee HC; Shiou YL; Jhuo SJ; Chang CY; Liu PL; Jhuang WJ; Dai ZK; Chen WY; Chen YF; Lee AS
Cardiovasc Diabetol; 2019 Apr; 18(1):45. PubMed ID: 30935417
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension.
Chen X; Yu X; Lian G; Tang H; Yan Y; Gao G; Huang B; Luo L; Xie L
Biomed Pharmacother; 2024 May; 174():116505. PubMed ID: 38574614
[TBL] [Abstract][Full Text] [Related]
7. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
[TBL] [Abstract][Full Text] [Related]
9. Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat.
Younis F; Leor J; Abassi Z; Landa N; Rath L; Hollander K; Naftali-Shani N; Rosenthal T
J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):358-371. PubMed ID: 29627992
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation.
Tang L; Cai Q; Wang X; Li X; Li X; Chen L; Yang Y
Clin Exp Hypertens; 2023 Dec; 45(1):2278205. PubMed ID: 37970663
[TBL] [Abstract][Full Text] [Related]
11. Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.
Cai C; Xiang Y; Wu Y; Zhu N; Zhao H; Xu J; Lin W; Zeng C
Mol Med Rep; 2019 Dec; 20(6):4984-4992. PubMed ID: 31702810
[TBL] [Abstract][Full Text] [Related]
12. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
13. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
14. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
Adão R; Mendes-Ferreira P; Santos-Ribeiro D; Maia-Rocha C; Pimentel LD; Monteiro-Pinto C; Mulvaney EP; Reid HM; Kinsella BT; Potus F; Breuils-Bonnet S; Rademaker MT; Provencher S; Bonnet S; Leite-Moreira AF; Brás-Silva C
Cardiovasc Res; 2018 Jul; 114(8):1165-1177. PubMed ID: 29584808
[TBL] [Abstract][Full Text] [Related]
15. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension.
Umar S; de Visser YP; Steendijk P; Schutte CI; Laghmani el H; Wagenaar GT; Bax WH; Mantikou E; Pijnappels DA; Atsma DE; Schalij MJ; van der Wall EE; van der Laarse A
Am J Physiol Heart Circ Physiol; 2009 Nov; 297(5):H1606-16. PubMed ID: 19783775
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M; Sala L; Rizzetto R; Staszewsky LI; Alemanni M; Zambelli V; Russo I; Barile L; Cornaghi L; Altomare C; Ronchi C; Mostacciuolo G; Lucchetti J; Gobbi M; Latini R; Zaza A
Cardiovasc Res; 2014 Oct; 104(1):37-48. PubMed ID: 25139747
[TBL] [Abstract][Full Text] [Related]
17. The selective PGI2 receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats.
Honda Y; Kosugi K; Fuchikami C; Kuramoto K; Numakura Y; Kuwano K
PLoS One; 2020; 15(10):e0240692. PubMed ID: 33057388
[TBL] [Abstract][Full Text] [Related]
18. Ursolic Acid Improves Monocrotaline-Induced Right Ventricular Remodeling by Regulating Metabolism.
Gao X; Zhang Z; Li X; Wei Q; Li H; Li C; Chen H; Liu C; He K
J Cardiovasc Pharmacol; 2020 Jun; 75(6):545-555. PubMed ID: 32141989
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary arterial hypertension induced by a novel method: Twice-intraperitoneal injection of monocrotaline.
Zhuang W; Lian G; Huang B; Du A; Xiao G; Gong J; Xu C; Wang H; Xie L
Exp Biol Med (Maywood); 2018 Aug; 243(12):995-1003. PubMed ID: 30099957
[TBL] [Abstract][Full Text] [Related]
20. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
